SYS-6002 is a monoclonal antibody conjugated commercialized by Corbus Pharmaceuticals, with a leading Phase II program in Solid Tumor. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of SYS-6002’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
The revenue for SYS-6002 is expected to reach an annual total of $48 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SYS-6002 Overview
SYS-6002 is under development for the treatment of advanced solid tumors, metastatic urothelial carcinoma, cervical cancer, prostate cancer and triple-negative breast cancer. The therapeutic candidate is a next-generation antibody-drug-conjugate (ADC) that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2 and monomethyl auristatin E (MMAE) as the payload. It is administered through parenteral route. It acts by targeting nectin 4.
Corbus Pharmaceuticals Overview
Corbus Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics to treat inflammatory and fibrotic diseases. The company’s pipeline product portfolio includes Lenabasum, an oral small-molecule for the treatment of inflammatory diseases; CRB-4001, to treat fibrotic diseases. It serves in the therapeutic areas of chronic inflammation, autoimmune diseases, allergies and orphan diseases. Corbus Pharmaceuticals collaborates with National Institutes of Health (NIH) for in the development of drugs. The company has operations in the UK and Australia. Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, the US.
For a complete picture of SYS-6002’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
